THE CANNABIS DRUGS.
ARE THEY WORKING ON BRAIN CANCERS AND ADHD?
In a release by the International Association for Cannabinoid medicines in February 2017 they refer to a cannabis extract with THC and CBD improved survival of patients with recurrent glioblastoma, a particularly aggressive brain tumour, if given together with standard therapy. This is the result of a placebo-controlled study with 21 patients, which was reported by the producer of the cannabis extract Sativex, GW Pharmaceuticals in the UK. The study showed that 83% of patients with documented recurrent glioblastoma treated with THC and CBD had survived the first year compared with 53% of patients in the placebo. A press release says directly from GW states: “GW conducted substantial pre-clinical oncologic research on several cannabinoids in various forms of cancer including brain, lung, breast, pancreatic, melanoma, ovarian, gastric, renal, prostate and bladder. These studies have resulted in approximately 15 publications and show the multi-modal effects of cannabinoids on a number of the key pathways associated with tumor growth and progression.” (1) February 2017
In a randomized-controlled trial on cannabinoids in attention-deficit/hyperactivity disorder it was stated that The cannabis extract Sativex improved hyperactivity and impulsivity in patients with ADHD (attention deficit hyperactivity disorder). The study was carried out by researchers of King’s College London and other medical institutions from London, UK. There was a significant improvement in hyperactivity/impulsivity and a trend for improvement in inattention, cognitive performance and emotional liability. Authors wrote that “although individual findings did not reach conventional significance levels, effects across multiple measures showed consistent improvements in cognition and behavior. ADHD may represent a subgroup of individuals that gain cognitive enhancement and reduction of ADHD symptoms from the use of cannabinoids.” The data were presented at the 29th ECNP Congress, 17-20 September 2016 in Vienna, Austria, and published in the European Neuropsychopharmacology. 30 patients with ADHD received either Sativex or placebo for four weeks. (2) August 2017
REFERENCES TO PRIMARY LITERATURE
SCIENCE/HUMAN: CANNABIS IMPROVED SURVIVAL OF PATIENTS WITH AGGRESSIVE BRAIN CANCER IN CONTROLLED CLINICAL STUDY. HTTPS://WWW.CANNABIS-MED.ORG/ENGLISH/BULLETIN/WW_EN_DB_CANNABIS_ARTIKEL.PHP?ID=499
CANNABINOIDS IN ATTENTION-DEFICIT/HYPERACTIVITY DISORDER: A RANDOMISED-CONTROLLED TRIAL. HTTPS://WWW.NCBI.NLM.NIH.GOV/PUBMED/28576350
APPRAISING THE “ENTOURAGE EFFECT”: ANTITUMOR ACTION OF A PURE CANNABINOID VERSUS A BOTANICAL DRUG PREPARATION IN PRECLINICAL MODELS OF BREAST CANCER HTTPS://WWW.SCIENCEDIRECT.COM/SCIENCE/ARTICLE/ABS/PII/S0006295218302387
ANTITUMOR ACTIVITY OF PLANT CANNABINOIDS WITH EMPHASIS ON THE EFFECT OF CANNABIDIOL ON HUMAN BREAST CARCINOMA. HTTPS://WWW.NCBI.NLM.NIH.GOV/PUBMED/20859676 PATHWAYS MEDIATING THE EFFECTS OF CANNABIDIOL ON THE REDUCTION OF BREAST CANCER CELL PROLIFERATION
ANTITUMOR EFFECTS OF CANNABIDIOL, A NONPSYCHOACTIVE CANNABINOID, ON HUMAN GLIOMA CELL LINES. HTTPS://WWW.NCBI.NLM.NIH.GOV/PUBMED/14617682
Cannabidiol (CBD) is a naturally occurring compound found in the resinous flower of cannabis.
Cannabigerol (CBG) is a non-psychoactive cannabinoid that plays an important role in the biochemistry of the cannabis plant. CBG acts as a chemical precursor to other cannabinoids such as THC and CBD. CBG reacts with the cannabinoid receptors in the brain. CBG, however, acts as a buffer to the psychoactivity of THC by working to alleviate the paranoia sometimes caused by higher levels of THC.